Kesimpta is a medication used to treat relapsing forms of multiple sclerosis (MS) and clinically isolated syndrome (CIS). Kesimpta comes as a solution inside single-dose prefilled injection pens or ...

Zenas Biopharma has acquired global rights to develop BTK inhibitor orelabrutinib to treat progressive forms of multiple ...

MS advocate and real estate investor Tamiko Ryan talks about the frustrations of getting proper treatments and shares strategies to help you get the support you need to manage MS and thrive. Multiple ...

A multicenter phase 3 trial comparing ocrelizumab to fingolimod for children with MS achieved its noninferiority primary ...

Discover the groundbreaking medical trial offering new hope for autoimmune diseases and the first courageous patient behind ...

Doctors have traditionally used a "step-up," also known as the "escalation," approach for treating multiple sclerosis (MS), the neurodegenerative disease that affects the central nervous system. Using ...

MILAN -- A path to a cure for multiple sclerosis (MS) may be on the horizon, a top MS researcher suggested. The field faces a great opportunity to advance from suppressing the disease to curing it, ...

A 24-parameter spectral flow cytometry panel was developed to monitor immune receptor expression in MS patients, aiding personalized treatment approaches. The panel detects 12 treatment-associated ...

Dr. David Gross, an ophthalmologist who practices in Merrillville, took up cycling more more than 20 years ago and has now raised more than $1 million in long-distance rides to find a cure for ...

Susie Wyss used to inject herself daily with a medication for multiple sclerosis. “The injection hurt. It caused welts, bruises, and sometimes permanent lipoatrophy,” Wyss told more than 800 people ...

Multiple sclerosis (MS) is a chronic, often progressive disease that affects the central nervous system, including the brain, spinal cord, and optic nerves. While the most common symptoms include ...

A preclinical study by biomedical scientists at the University of California, Riverside, has shown why some people with ...